Literature DB >> 1905848

Reproducibility of one-stage, two-stage and chromogenic assays of factor VIII activity: a multi-center study.

S Cinotti1, G Longo, A Messori, M Morfini, M Blomback, K Schimpf, K Schumacher, H Kjellman, A Novakova-Banet, U Delvos.   

Abstract

This study was aimed at assessing the reproducibility of Factor VIII assays between different laboratories using the same reagents. A total of 176 post-dose plasma samples were obtained from 8 Italian subjects with hemophilia-A treated with a single dose of Factor VIII concentrates. Three laboratories (in FRG, Italy, and Sweden) participated in the study. Frozen aliquots of each sample were dispatched to each of the laboratories, where the aliquots were assayed using the same one-stage, two-stage and chromogenic methods. The one-stage and the chromogenic methods were well reproducible between the three centers: pairwise correlation analyses yielded r-values ranging from 0.88 to 0.91 for the one-stage method and from 0.91 to 0.96 for the chromogenic method. The agreement between these two assays was less evident in samples with activity below 200 IU/L in which the one-stage gave, on average, higher Factor VIII concentrations than those provided by the chromogenic method. The two-stage method was not well reproducible, and the pairwise r-values ranged from 0.48 to 0.73. Our study emphasises the need to develop multi-center quality control programs to verify the reproducibility of Factor VIII assays.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1905848     DOI: 10.1016/0049-3848(91)90652-d

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  3 in total

1.  The "normal" factor VIII concentration in plasma.

Authors:  Saulius Butenas; Behnaz Parhami-Seren; Anetta Undas; David N Fass; Kenneth G Mann
Journal:  Thromb Res       Date:  2010-05-07       Impact factor: 3.944

Review 2.  The History of Clotting Factor Concentrates Pharmacokinetics.

Authors:  Massimo Morfini
Journal:  J Clin Med       Date:  2017-03-20       Impact factor: 4.241

3.  Factor VIII inhibitor development in Egyptian hemophilia patients: does intron 22 inversion mutation play a role?

Authors:  Laila M Sherief; Osama A Gaber; Hala Mosaad Youssef; Hanan S Sherbiny; Wesam A Mokhtar; Asmaa A A Ali; Naglaa M Kamal; Yehia H Abdel Maksoud
Journal:  Ital J Pediatr       Date:  2020-09-14       Impact factor: 2.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.